Natco Pharma, a leading pharmaceutical company, reported strong financial performance in the fourth quarter of the fiscal year 2023-24 (Q4FY24).
Key Financial Highlights (Q4FY24):
Total Revenue: ₹11,103 million
Pharma Exports Formulations: ₹9,549 million
EBITDA: ₹5,393 million (EBITDA Margin: 48.6%)
Profit Before Tax (PBT): ₹4,776 million
Profit After Tax (PAT): ₹3,863 million
Other Key Points:
Strong Growth: Natco Pharma demonstrated significant growth in revenue and profitability during Q4FY24.
Key Growth Drivers: The growth was primarily driven by strong performance in the export formulations segment.
Investment: The company made a strategic investment of USD 2 million in Cellogen Therapeutics Private Ltd., a company with R&D programs involving Cell and Gene Therapy Solutions.
Stock Performance: Shares of Natco Pharma surged after the announcement of the Q4 results, hitting a new 52-week high.
For more detailed analysis and insights on Natco Pharma's Q4FY24 results, you can refer to the following resources:
ICICI Direct Analysis: https://www.icicidirect.com/stocks/natco-pharma-ltd-share-price
5paisa Share Price: https://www.5paisa.com/stocks/natcopharm-share-price
The Economic Times: https://economictimes.indiatimes.com/topic/natco-pharma-ltd-q4-results
Business Standard: https://www.business-standard.com/markets/news/natco-pharma-stock-surges-8-hits-new-52-week-high-on-strong-q4-show-124052800577_1.html
Comments